Manager × security

HighVista Strategies LLC VRDN holdings history

Who else holds this security? →

VIRIDIAN THERAPEUTICS INC · CUSIP 92790C104 · CIK 1335325

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, HighVista Strategies LLC reported 159.88K VRDN (shares), valued at $2.94M, or 0.67% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.67%
Shares
159.88K
159,885
Reported value
$2.94M
USD

Shares increased 19.11%; reported value increased 11.87%, and weight changed -0.05 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.67%159,885SEC filing ↗Filed Aug 14, 2026
Q1 20260.72%134,229SEC filing ↗Filed May 15, 2026
Q4 20252.99%372,472SEC filing ↗Filed Feb 17, 2026
Q3 20252.48%469,335SEC filing ↗Filed Nov 14, 2025
Q2 20252.49%484,559SEC filing ↗Filed Aug 14, 2025
Q1 20250.94%180,551SEC filing ↗Filed May 15, 2025
Q4 20241.10%154,563SEC filing ↗Filed Feb 14, 2025
Q3 20241.45%185,240SEC filing ↗Filed Nov 14, 2024
Q2 20240.94%198,484SEC filing ↗Filed Aug 14, 2024
Q1 20241.24%198,484SEC filing ↗Filed May 15, 2024
Q4 20231.57%198,484SEC filing ↗Filed Feb 14, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20231.57%198,484$4.32MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 20241.24%198,484$3.48MShares unchanged; reported value decreased 19.61%, and weight changed -0.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20240.94%198,484$2.58MShares unchanged; reported value decreased 25.70%, and weight changed -0.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20241.45%185,240$4.21MShares decreased 6.67%; reported value increased 63.20%, and weight changed +0.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20241.10%154,563$2.96MShares decreased 16.56%; reported value decreased 29.69%, and weight changed -0.35 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20250.94%180,551$2.43MShares increased 16.81%; reported value decreased 17.86%, and weight changed -0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20252.49%484,559$6.77MShares increased 168.38%; reported value increased 178.33%, and weight changed +1.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20252.48%469,335$10.13MShares decreased 3.14%; reported value increased 49.51%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20252.99%372,472$11.59MShares decreased 20.64%; reported value increased 14.45%, and weight changed +0.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20260.72%134,229$2.63MShares decreased 63.96%; reported value decreased 77.35%, and weight changed -2.27 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20260.67%159,885$2.94MShares increased 19.11%; reported value increased 11.87%, and weight changed -0.05 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
HighVista Strategies LLC · VIRIDIAN THERAPEUTICS INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1335325","quarter":"2026Q2","cusip":"92790C104"}

get_institutional_manager_history
{"cik":"1335325","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.